Skip to main content

IDWeek 2024 Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

290 Views

T2. Studies of empiric and pre-emptive therapy

Poster Session: Transplant: Studies of Empiric and Preemptive Therapy

(P-2305) Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam [C/T] Real-world Analysis Results (SPECTRA): Results of the Immunocompromised Patients

Saturday, October 19, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Presenting Author(s)

Emre Yucel, PhD

Principal Scientist
Merck & Co., Inc.
North Wales, Pennsylvania, United States

Co-Author(s)

AS

Alex Soriano, MD

Infectious Disease
Hospital Clínic de Barcelona
Barcelona, Catalonia, Spain
DP

David Paterson

National University of Singapore, Singapore
FT

Florian Thalhammer, MD

Infectious Disease specialist
Medizinische Universität Wien
Vienna, Wien, Austria
SK

Stefan Kluge, Prof. Dr. med.

Director
Department of Intensive Care, University Medical Center Hamburg-Eppendorf
Hamburg, Hamburg, Germany
PV

Pierluigi Viale, n/a

MD
Infectious Diseases Unit, Department of Medical and Surgical Sciences, Policlinico Sant'Orsola Malpighi, University of Bologna, Bologna, Italy
Bologna, Emilia-Romagna, Italy
MA

Mike Allen, PhD

MSD, UK, Ltd.
London, England, United Kingdom
BA

Brune Akrich, MD

Associate Director Medical Affairs
Merck Research Labs, MSD
Puteaux, Ile-de-France, France
YZ

Yanbing Zhou, PhD

Merck
Rahway, New Jersey, United States
HY

Huina Yang, MD, MBBS, FRCPath

Tan Tock Seng Hospital
Singapore, Singapore
SK

Sundeep Kaul, PHD FRCP FFICM

Dr
Harefield hospital
london, England, United Kingdom